Articles Vol. 67 No. CĐ8-NCKH 06/07/2026

EVALUATION OF THE EFFECTIVENESS OF ALMARIDERM VERO MELASCREEN IN THE TREATMENT OF MELASMA AT CA MAU EYE-DERMATOLOGY HOSPITAL IN 2024-2025

Ngo Thanh Tan1,2, Le Thanh Thoang1,2, Trinh Thao Trinh1,2, Doan Thuy Thanh Truc1,2, Duong Thi Thu Suong1,2
1 Ca Mau Provincial Eye and Dermatology Hospital
2 Bệnh viện Mắt - Da liễu tỉnh Cà Mau
DOI: 10.52163/yhc.v67iCD8.5671
34 Views
0 Downloads
Abstract

Objectives: To investigate the clinical characteristics of melasma and to evaluate the effectiveness of Almariderm Vero Melascreen in the treatment of melasma among patients at Ca Mau Eye–Dermatology Hospital in 2024–2025.Methods: This was an interventional study with prospective longitudinal follow-up, conducted on 36 patients diagnosed with melasma who presented to Ca Mau Eye–Dermatology Hospital in 2024 and 2025. Descriptive and analytical statistical methods were applied, along with appropriate statistical tests. Statistical significance was set at p < 0.05. Results: The mean melasma area and severity index (MASI) score after treatment with Almariderm Vero Melascreen decreased markedly from 13.4 ± 3.9 (n = 36) at baseline to 7.3 ± 2.5 (n = 36) after 12 weeks of treatment. The severity of melasma showed substantial improvement compared with baseline, with the proportion of patients with severe and very severe melasma decreasing by more than 60.0% after treatment. Transient adverse effects were mild and included slight burning sensation (8.3%) and mild erythema (5.6%). Conclusions: Treatment of facial melasma with Almariderm Vero Melascreen is an effective and safe therapeutic option. However, a relatively prolonged treatment duration is required.

References
[1]
Pearl E Grimes M. Melasma: Epidemiology, pathogenesis, clinicalpresentation, and diagnosis. UpToDate. 2023; Google Scholar
[2]
Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. Oct 2011;65(4):699-714. doi:10.1016/j.jaad.2011.06.001 Google Scholar
[3]
Perper M, Eber AE, Fayne R, et al. Tranexamic Acid in the Treatment of Melasma: A Review of the Literature. Am J Clin Dermatol. Jun 2017;18(3):373-381. doi:10.1007/s40257-017-0263-3 Google Scholar
[4]
Kaur A, Bhalla M, Sarkar R. Tranexamic acid in melasma: a review. Review Article. Pigment International. January 1, 2020 2020;7(1):12-25. doi:10.4103/Pigmentinternational.Pigmentinternational_9_20 Google Scholar
[5]
Nguyễn Thị Thùy Linh. Đặc điểm lâm sàng nám da tại BV Da liễu TW. Tạp chí Y học Việt Nam. Tập 524 Số 1A (2023). Google Scholar
[6]
Ortonne JP. Melasma. J Eur Acad Dermatol. 2009. Google Scholar
[7]
Kang HY. Melasma in Asians: A clinical review. Pigment Cell Res. 2018. Google Scholar
[8]
Boukari F. Topical depigmenting agents review. Dermatol Ther. 2015. Google Scholar
[9]
Torok HM. Novel skin-lightening complex. Cutis. 2017. Google Scholar
[10]
Chan RC. Multi-active melasma therapy. Dermatol Ther. 2020. Google Scholar
[11]
Grimes PE. Hydroquinone irritation profile. Cutis. 2006. Google Scholar